NOG anticorps

N° du produit ABIN1737420

Détail du produit anti-NOG anticorps

Antigène: NOG (Noggin (NOG))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp NOG est non-conjugé

Application: Western Blotting (WB)

Specificité: Reacts with human Noggin

Réactivité croisée: Souris

Réactivité croisée (Details): Cross reacts with mouse and rat.

Purification: Antigen affinity purified

Immunogène: Synthetic peptide comprising an internal sequence of the human Noggin protein. Sequence is 100% conserved in rat and mouse.

Isotype: IgG

Information d'application

Indications d'application:

Working dilution: Optimal dilution should be determined by the end user.
The following are guidelines only:
- WB :1/1 000 to 1/2 000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: PBS, Sodium azide 0.02 %

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C/-20 °C

Stockage commentaire: Short term storage at +4°C. For extended periods store in aliquots at -20°C. Antibodies are guaranteed for 6 month from date of receipt.

Date de péremption: 6 months

Détails sur NOG

Antigène: NOG (Noggin (NOG))

Autre désignation: Noggin (NOG Produits)

Synonymes: anticorps SYM1, anticorps SYNS1, anticorps nog-A, anticorps nog1, anticorps noggin-1, anticorps noggin, anticorps noggin, anticorps noggin L homeolog, anticorps noggin protein, anticorps NOG, anticorps Nog, anticorps nog.L, anticorps noggin

Sujet: Noggin is involved in numerous developmental processes, such as neural tube fusion and joint formation. The morphogenesis of organs is initiated by a downgrowth from a layer of epithelial stem cells. This process is achieved through the receipt of signals from 1) a WNT protein (WNT3A) to stabilize beta-catenin, and 2) Noggin, which is a bone morphogenetic protein inhibitor. Noggin mutations in unrelated families with proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1) have been identified, which have multiple joint fusion as their principal defect.

Pathways: Stem Cell Maintenance, Tube Formation